A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia

NCT04043104 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Radiation-Induced Parotid Gland Hypofunction
Xerostomia Due to Radiotherapy
Head and Neck Cancer

Interventions

DRUG: AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
DRUG: AAV2hAQP1: 3 x 10^10 vg/gland (both glands)
DRUG: AAV2hAQP1: 3 x 10^11 vg/gland (single gland)
DRUG: AAV2hAQP1: 1 x 10^11 vg/gland (both glands)
DRUG: AAV2hAQP1: 1 x 10^12 vg/gland (single gland)
DRUG: AAV2hAQP1: 3 x 10^11 vg/gland (both glands)
DRUG: AAV2hAQP1: 3 x 10^12 vg/gland (single gland)
DRUG: AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

Sponsor

MeiraGTx UK II Ltd